News | Telecardiology | May 15, 2020

Telemedicine-based Network Offers Remote Guidance to 100 Million STEMI Patients

Study investigators have created a template for reducing disparities in STEMI management between developed and developing countries

The protocol chart for the LATIN STEMI telecardiology program.

The protocol chart for the LATIN STEMI telecardiology program.


May 15, 2020 – A groundbreaking trial recently examined the viability of telemedicine for remote guidance of a population-based ST-segment elevation myocardial infarction (STEMI) program reaching more than 100 million patients. The study, presented as late-breaking science during the Society for Cardiovascular Angiography and Interventions (SCAI) 2020 Virtual Conference

The study helps further prove that telecardiology transcends boundaries, enabling millions of patients to have STEMI care access.

Telemedicine allows healthcare professionals to evaluate, diagnose and treat patients at a distance using telecommunications technology. Within the last decade, the approach has seen striking evolution and in the current COVID-19 climate, has become increasingly important to ensure patients have access to the care they need.

During the study, patients were triaged at spokes that included small clinics and primary healthcare centers in remote locations and transferred to hubs with percutaneous coronary intervention (PCI)-capability. The Latin America Telemedicine Network (LATIN) functioned between 2013 to present in four countries – Brazil, Colombia, Mexico and Argentina.

"As Americans see the benefits of telemedicine in the COVID-19 era, the findings of the [LATIN investigation] should be more relevant and noteworthy,” said Sameer Mehta, M.D., lead author and chairman of the Lumen Foundation. “LATIN is the result of dedicated efforts of more than 2,000 healthcare professionals, including about 600 physicians that were involved in this decade old program.”

Almost 900,000 patients presenting at 351 remote locations were triaged through a STEMI network. The program provided an umbrella of AMI protection to more than 100 million patients in Brazil, Colombia, Mexico, and Argentina. Mortality was reduced by 55 percent and the program contributed to saving $291 million. The results from LATIN trial surpass the total accumulated global experience with telemedicine.

The study investigators tested and proved four attributes of telemedicine:
   • Increased access • Increased accuracy.
   • Cost-effectiveness. 
   • Comprehensive, population-based care and delivery of guidelines-based acute myocardial infarction (AMI) management.

The program was created as a hub and spoke model that was used to expand access. Patients presented at remote clinics and primary care centers and were guided through telemedicine to receive thrombolysis, pharmaco-invasive management, or primary PCI. The role of the telemedicine experts was two-fold: urgent and accurate STEMI diagnosis and tele consultation of the entire STEMI process. Time to telemedicine diagnosis (TTD) was 3.5 minutes and it was possible from tremendous investment in IT infrastructure, with use of cloud computing, business intelligence tools and with GPS navigation. LATIN established TTD as a novel metric of telemedicine efficiency.

“LATIN has established the role of telemedicine in cost-effective and population-based management of AMI that reduces disparities of AMI care between developed and developing countries,” said Mehta. “It has provided a template that can be most beneficial for poorer regions on the world, including in sub-Saharan Africa, the Middle East and in southeast Asia. LATIN can also serve as a model of providing population-based coverage for other systems guided entities such as stroke."

Find links to the rest of the SCAI late-breaking trials and other SCAI news

 


Related Content

News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or ...

Home June 20, 2024
Home
Subscribe Now